Inflammatory Markers and Adipokines Related to Cardiovascular Risk and Metabolic Comorbidities in Psoriatic Arthritis treated with Apremilast

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Apremilast (Primary)
Indications Psoriatic arthritis
Focus Pharmacodynamics; Therapeutic Use

Most Recent Events

24 Oct 2018 Results presented at the 82nd American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
17 Jul 2018 New trial record
16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight